Trials / Completed
CompletedNCT02266966
Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The aim of this functional Magnetic Resonance Imaging (MRI) study is to assess the effect of single dose of F2695 at 75mg on modulation of the cerebral motor network.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F2695 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2014-10-17
- Last updated
- 2016-10-13
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02266966. Inclusion in this directory is not an endorsement.